Within healthcare, the Inflation Reduction Act (IRA) aims to improve affordability and accessibility by lowering prescription drug prices and out-of-pocket costs for Medicare beneficiaries and extending premium subsidies in the Affordable Care Act’s (ACA) marketplaces.
Sweeping proposals introduced by the act represent some of the most significant healthcare legislation since the ACA by giving Medicare the ability to negotiate drug prices with manufacturers. In this paper, we discuss potential implications of these policies for how drug manufacturers manage their portfolios.
